Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.

NCT00055510 is registered in ClinicalTrials.gov with Chugai Pharma USA as lead sponsor.

NCT NCT00055510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00055510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Blinded Study Conducted at Multiple Centers Evaluating Various Doses of an Investigational Agent (BO-653) Against Placebo, for Safety and Effectiveness in Preventing Post-Angioplasty Blood Vessel Re-Closure (Restenosis) in Stented Vessels.
Lead sponsor
Chugai Pharma USA
Phase
Phase 2/3
Overall status
Completed
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

atherosclerosis, coronary restenosis, graft occlusion, vascular